This trial is active, not recruiting.

Condition full thickness skin defects
Treatment novomaix dermal substitute in combination with stsg
Phase phase 1
Sponsor Association of Dutch Burn Centres
Collaborator Ernst Reichmann Tissue Biology Research Unit Zürich
Start date June 2013
End date December 2015
Trial size 20 participants
Trial identifier NCT02164760, ESG-09-2012, NL42113.094.12


In this study the safety and feasibility of an acellular dermal template (Novomaix), combined with split thickness skin grafts, for use in patients with full thickness skin defects, is tested. Results will be compared intra-patient with those obtained after conventional treatment with split thickness skin grafts. We expect this treatment to be safe, and to provide better outcome regarding scar quality.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, outcomes assessor)
Primary purpose treatment
Novomaix dermal substitute in combination with STSG
novomaix dermal substitute in combination with stsg Novomaix
Novomaix dermal substitute in combination with STSG
(No Intervention)
STSG alone

Primary Outcomes

Graft take (experimental vs control area)
time frame: 5-7 days postoperative

Secondary Outcomes

time frame: 5-7 and 18 ± 2 days days postoperative
Complication rate
time frame: Up to 12 months postoperative
Scar quality
time frame: 3 months
Scar quality
time frame: 6 months
Scar quality
time frame: 9 months
Scar quality
time frame: 12 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Age ≥18 years 1. with acute burns/trauma wounds that require skin grafting (group 1) OR 2. with scar problems requiring surgical treatment (group 2) - Full thickness skin defects of 50 cm2 or more, but <50% TBSA - Skin defects must be configured in such a way that two areas of 25 cm2 can be grafted - Informed consent by the patient Exclusion Criteria: - Patients with infected wounds - Pregnant or breast feeding females - Patients with known concomitant medical conditions that may interfere with normal wound healing (e.g. immune deficiency, HIV, diabetes, collagenoses, cancer) - Known allergy against porcine collagen or elastin - Patients who are expected (according to the responsible medical doctor) to be noncompliant to the study protocol. (This includes patients with severe cognitive dysfunction/impairment and severe psychiatric disorders) - Previous enrolment of the patient into the current study

Additional Information

Official title A Phase 1, Randomized, Multicentre Multinational Study to Evaluate the Safety and Feasibility of an Acellular Dermal Template Novomaix for the Treatment of Full Thickness Skin Defects in Human Patients.
Principal investigator Esther Middelkoop, Prof. dr.
Description Using dermal substitutes in combination with a split-thickness skin graft (STSG) is a well acknowledged therapy in burns and reconstructive surgery. Nevertheless, the ideal substitute is not available yet. We therefore want to investigate the use of an acellular dermal template (Novomaix), in combination with STSG, to treat these defects. Adult patients with acute (burn) wounds (group 1) and scars (group 2) will be included in this study. This phase I study aims to investigate the safety and feasibility of the use of this dermal matrix, with regard to graft take, epithelialisation and complications after transplantation. Moreover, scar quality will be evaluated.
Trial information was received from ClinicalTrials.gov and was last updated in June 2015.
Information provided to ClinicalTrials.gov by Association of Dutch Burn Centres.